109,959 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 109,959 shares of the company’s stock, valued at approximately $1,385,000.

A number of other hedge funds also recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth about $26,000. Federated Hermes Inc. raised its holdings in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Spire Wealth Management lifted its position in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares in the last quarter. Transamerica Financial Advisors LLC lifted its position in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Finally, Comerica Bank boosted its stake in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $16.97 on Thursday. The company’s 50 day moving average price is $14.04 and its 200 day moving average price is $13.51. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.66 and a 52 week high of $17.86. The company has a market capitalization of $5.41 billion, a PE ratio of 44.66 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 17.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, UBS Group assumed coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.